| |APRIL 20258INDIA FOCUSES ON PHARMA AND MEDTECH RESEARCH TO DRIVE MEDICAL ADVANCESAlembic Pharmaceuticals Ltd has joined forces with Amlan International, the animal health arm of Oil-Dri Corporation of America, to bring cutting-edge poultry health solutions to India.This team-up will make it easier to get groundbreaking feed additives that boost health care, help absorb nutrients better, and get the most out of feed conversion ratio (FCR). In the end, this will lead to higher poultry yields and meet the growing need for top-notch protein in the industry. The partnership will help share know-how provide hands-on training, and support long-term growth in India's poultry sector, as stated in an official announcement on Tuesday."At Alembic, we have always believed in driving innovation that creates real impact. Partnering with Amlan International is a step towards that goal, allowing us to bring scientifically backed, practical solutions to poultry farmers across India. With Amlan's expertise in toxin binder & gut health, and with our strong presence in the market, we're not just introducing new products, we're addressing key challenges in poultry farming. Our long term goal is to improve efficiency and contribute towards a more sustainable future for the industry", said, Shaunak Amin, Managing Director, Alembic Pharmaceuticals Ltd."This strong foundation of partnership will open the door with innovative and research based products broadly reaching India's poultry and feed milling sector. It is a pleasure for Amlan International to collaborate with Alembic Pharmaceuticals India that has a strong legacy with a global footprint. This agreement will lay the framework for cultivating success through strong collaboration, continuous learning, knowledge sharing, and an innovative range of products to enhance poultry productivity", added, W. Wade Robey, VP of Agriculture, Oil-Dri Corporation of America and President of Amlan International. POWith a strategic focus on positioning India as a global R&D center in pharmaceutical and medical technology, the Government's launch of the Expression of Interest (EOI) focuses on promoting research and innovation in the Pharma MedTech Sector (PRIP) scheme. The initiative aims to boost investments in drug discovery, medical devices and advanced therapeutics with a complete financial outlay of Rs 5,000 Cr.A 32-page EoI document has been issued by the Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilizers, promoting participation from pharmaceutical and medical device manufacturers. The document comments "to provide you with an opportunity to co-shape India's journey towards becoming an R&D innovation hub."The initiative focuses on six research spaces, including Medical Devices, Orphan Drugs, New Chemical and Biological Entities, Complex Generics and Biosimilars, Precision Medicine, and Antimicrobial Resistance (AMR).To attract industry participation, the scheme delivers subsidies in three categories. Giant pharmaceutical and medtech firms can obtain up to 35% of the total cost of the project or Rs 125 Cr. Another category offers Rs 100 Cr for plans at TRL 5 or 6, whereas startups and MSMEs can receive Rs 1 Cr per project at the early stage of research.With this scheme, India seeks to foster its pharmaceutical innovation, strengthen leadership in MedTech R&D and attract global investments. POTOP STORIESALEMBIC PHARMA JOINS AMLAN TO INTRODUCE POULTRY HEALTH SOLUTIONS IN INDIA
< Page 7 | Page 9 >